CD79A and COVID-19: Variability in the ability to elicit an effective IgA response, whether through direct stimulation of secretory IgA production or through translocation from the serum, may offer a potential explanation for the significant variability seen in the ability of COVID-19 vaccines to prevent symptomatic illness and secondary transmission.